Izmir Biomedicine and Genome Center, Izmir 35340, Turkey.
Department of Genome Sciences and Molecular Biotechnology, Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir 35340, Turkey.
Int J Mol Sci. 2020 Sep 1;21(17):6342. doi: 10.3390/ijms21176342.
Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the mesothelial cells lining the pleural surface of the chest wall and lung. The etiology of MPM is strongly associated with prior exposure to asbestos fibers, and the median survival rate of the diagnosed patients is approximately one year. Despite the latest advancements in surgical techniques and systemic therapies, currently available treatment modalities of MPM fail to provide long-term survival. The increasing incidence of MPM highlights the need for finding effective treatments. Targeted therapies offer personalized treatments in many cancers. However, targeted therapy in MPM is not recommended by clinical guidelines mainly because of poor target definition. A better understanding of the molecular and cellular mechanisms and the predictors of poor clinical outcomes of MPM is required to identify novel targets and develop precise and effective treatments. Recent advances in the genomics and functional genomics fields have provided groundbreaking insights into the genomic and molecular profiles of MPM and enabled the functional characterization of the genetic alterations. This review provides a comprehensive overview of the relevant literature and highlights the potential of state-of-the-art genomics and functional genomics research to facilitate the development of novel diagnostics and therapeutic modalities in MPM.
恶性胸膜间皮瘤(MPM)是一种罕见的、侵袭性的胸膜间皮细胞癌,位于胸壁和肺的胸膜表面。MPM 的病因与先前暴露于石棉纤维密切相关,确诊患者的中位生存率约为一年。尽管在手术技术和系统治疗方面取得了最新进展,但目前 MPM 的治疗方法仍无法提供长期生存。MPM 发病率的上升凸显了寻找有效治疗方法的必要性。靶向治疗在许多癌症中提供了个性化治疗。然而,由于靶点定义不佳,临床指南不推荐 MPM 的靶向治疗。为了确定新的靶点并开发精确有效的治疗方法,需要更好地了解 MPM 的分子和细胞机制以及不良临床结局的预测因素。基因组学和功能基因组学领域的最新进展为 MPM 的基因组和分子谱提供了突破性的见解,并实现了遗传改变的功能特征分析。本综述提供了相关文献的全面概述,并强调了最先进的基因组学和功能基因组学研究在促进 MPM 新型诊断和治疗方法开发方面的潜力。